A Phase 1 Study of BHV-1530 in Advanced Solid Tumors
Part of paid clinical trials in Newport Beach, California.
- Sponsor
- Biohaven Therapeutics Ltd.
- Study ID
- NCT06874335
- Phase
- PHASE1
- Status
- Recruiting
Conditions
- Solid Tumor
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- BHV-1530 — DRUGBHV-1530 will be administered as an IV infusion on Day 1 of each 21-day cycle
- Cemiplimab — DRUGcemiplimab (350 mg) will be administered as an IV infusion on Day 1 of each 21-day cycle
Study Details
This is a Phase 1, first in human (FIH), Open-Label, Dose Escalation, Dose Expansion and Dose Optimization Study of BHV-1530 as Monotherapy and in Combination with Other Anti-Cancer Agents in Adult Participants with Advanced or Metastatic Solid Tumors
Key Dates
- First listed
- Mar 13, 2025
- Start date
- Mar 20, 2025
- Status verified
- Jul 2026
- Primary completion
- Mar 31, 2029
- Completion
- Mar 31, 2029
Study Design
- Enrollment
- 140 participants (estimated)
- Allocation
- NON_RANDOMIZED
- Intervention model
- SEQUENTIAL
- Primary purpose
- TREATMENT
Arms
- Experimental: BHV-1530 Monotherapy
- Experimental: Experimental: BHV-1530 in combination with Cemiplimab
Primary Outcome Measure
Dose-escalation and Dose-expansion Cohorts: To determine the safety profile, maximum tolerable dose (MTD), minimally reproducible active dose (MRAD), and recommended dose range (RDR) of BHV-1530 monotherapy and BHV-1530 in combination with cemiplimab [ Time Frame: Through study completion, estimated as an average of 48 months ]
Central Contacts
- Chief Medical Officer203-404-0410
Locations (17)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Site-111 | Newport Beach | California | 92663 | - |
| Site-107 | Denver | Colorado | 80218 | - |
| Site-108 | Lake Mary | Florida | 32746 | - |
| Site-121 | Miami | Florida | 33136 | - |
| Site-118 | Orlando | Florida | 32804 | - |
| Site-120 | Ann Arbor | Michigan | 48109 | - |
| Site-110 | Detroit | Michigan | 48201 | - |
| Site-115 | Durham | North Carolina | 27710 | - |
| Site-122 | Cleveland | Ohio | 44195 | - |
| Site-112 | Myrtle Beach | South Carolina | 29572 | - |
| Site-116 | Nashville | Tennessee | 37203 | - |
| Site-103 | Austin | Texas | 78758 | - |
| Site-104 | Houston | Texas | 77030 | - |
| Site-101 | Irving | Texas | 75039 | - |
| Site-105 | San Antonio | Texas | 78229 | - |
| Site-106 | West Valley City | Utah | 84119 | - |
| Site-102 | Fairfax | Virginia | 22031 | - |
Find similar trials in Newport Beach, CA
Related Studies
- A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)PHASE1/PHASE2 · Recruiting · Merck Sharp & Dohme LLC · Aurora, Colorado
- Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of RecurrenceEARLY_PHASE1 · Recruiting · Miller Children's & Women's Hospital Long Beach · Long Beach, California
- Dabrafenib and/or Trametinib Rollover StudyPHASE4 · Recruiting · Novartis Pharmaceuticals · Scottsdale, Arizona
- Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid TumorsRecruiting · National Cancer Institute (NCI) · Bethesda, Maryland